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INTRODUCTION
Colorectal cancer (CRC) is a neoplasia affecting 
mucosa of large intestine and that develops through a 
multistage process resulting from the accumulation of 
multiple genetic mutations [1]. One of the most important 
alterations underlying CRC is the constitutive activation 
of Wnt/ß-catenin signalling, which leads to nuclear 
translocation of ß-catenin [2].
Epithelial-mesenchymal transition (EMT) is a 
process consisting in trans-differentiation of epithelial 
cells into motile mesenchymal cells. Even though it is 
a physiological process observed during development, 
wound healing and stem cell regulation, EMT is a hallmark 
of cancer progression as well [3]. Both in physiological 
and in pathological conditions, the transition follows a 
common and conserved programme, although having 
different characteristics depending on the tissue type. 
Independently from the context, EMT key events are 
the dissolution of epithelial cell-cell junctions and the 
gain of front-rear polarity in place of a basal-apical one. 
Furthermore, a reorganization of the cytoskeleton takes 
place, followed by changes in cell shape, acquisition 
of motility and, in many cases, the ability to degrade 
extracellular matrix [4]. All these events are supported by a 
down-regulation of epithelial-related genes’ expression in 
favour of an increased expression of mesenchymal specific 
genes. One of the most important hallmarks of EMT is 
the loss by cleavage of E-cadherin, a fundamental marker 
of epithelial phenotype, followed by the expression of 
N-cadherin, a known marker of mesenchymal phenotype. 
Wnt is one of the central pathways involved in promoting 
EMT in crosstalk with tyrosine kinase receptors, TGFß 
and Notch pathways. The gene expression changes 
contributing to EMT involve master regulators including 
SNAIL, TWIST and ZEB that are activated from the 
initial stages of transition [5–7]. Snail proteins (1 and 
2) and ZEB transcription factors repress epithelial genes 
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ABSTRACT
The mRNA-destabilizing protein ZFP36 has been previously described as a 
tumor suppressor whose expression is lost during colorectal cancer development. In 
order to evaluate its role in this disease, we restored ZFP36 expression in different 
cell contexts, showing that the presence of this protein impairs the epithelial-to-
mesenchymal transition (EMT) and induces a higher susceptibility to anoikis. 
Consistently, we found that ZFP36 inhibits the expression of three key transcription 
factors involved in EMT: ZEB1, MACC1 and SOX9. Finally, we observed for the first time 
that its expression negatively correlates with the activity of Wnt/β-catenin pathway, 
which is constitutively activated in colorectal cancer. This evidence provides a clue 
on the mechanism leading to the loss of ZFP36 in CRC. 
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or induce mesenchymal gene expression by binding to 
E-box sequences through their DNA binding domains. 
TWIST proteins are basic helix-loop-helix (bHLH) 
transcription factors and, similarly to SNAIL, they down-
regulate epithelial genes and activate mesenchymal genes’ 
expression. Other genes, such as Sex-determining Region 
Y box 9 (SOX9) and Metastasis-associated in colon 
cancer-1 (MACC1) are dysregulated in colon carcinoma 
and play a fundamental role at the onset of EMT [8, 9].
ZFP36 is the prototypic member of the TIS11/
ZFP36 family of RNA destabilizing proteins [10]. The 
RNA-binding specificity resides in the central tandem 
zinc finger domain which interacts at a nanomolar 
affinity level with mRNA molecules containing in their 
3ʹ untranslated region (3ʹUTR) ARE sequences mostly 
found in the form of the pentamer AUUUA or the nonamer 
UUAUUUAUU [10]. The discovery of ZFP36’s role as an 
mRNA decay factor firstly came from the characterization 
of ZFP36 specific knockout mice, which showed a chronic 
inflammatory phenotype. Further evidences followed 
showing the ability of ZFP36 to destabilize mRNAs 
encoding for several pro-inflammatory cytokines [11]. 
More recently, ZFP36 has been linked to cancer thanks 
to evidences showing its down-regulated state in several 
tumours including CRC, and the demonstration of its 
ability to regulate the expression of many oncogenic 
targets carrying ARE sequences in their 3ʹ UTR 
[12, 13]. In other words, although there is no evidence 
showing that the gene encoding for ZFP36 is a target of 
genomic loss or rearrangement, it appears to behave as a 
tumour suppressor. Particularly, it has been very recently 
demonstrated that ZFP36 is capable of inducing a shift 
from mesenchymal to epithelial phenotype in different 
cancer cell lines through the down-regulation of TWIST1 
and SNAIL1 [14].
In this study, we investigated the biological meaning 
of the loss of ZFP36 in CRC. Specifically, we confirmed 
that by restoring ZFP36 expression in different CRC 
cell lines, EMT appears to be inhibited while a higher 
susceptibility to anoikis occurs. This evidence depends on 
the downregulation of different ZFP36’s oncogenic targets 
among whom we validated SOX9, MACC1 and ZEB1 
that were never described previously as ZFP36 targets. 
Moreover, in the absence of genomic loss, we provide 
evidence suggesting that ZFP36 downregulation in CRC 
is inversely correlated to Wnt/β-catenin constitutive 
activation, providing new insights into loss of post-
transcriptional regulatory circuits during CRC tumour 
development and progression.
RESULTS 
ZFP36 expression in colon cancer
We analysed ZFP36 expression in a specific dataset 
described in Materials and Methods. According to gene 
expression profiles, in the 80 samples considered – 
composed of 23 normal colon mucosa (Normal), 30 
primary colon carcinoma (CRC) and 27 liver metastases 
(Mts) – the expression of ZFP36 gene is significantly 
decreased when comparing primary tumour with normal 
counterpart (Figure 1A). The same gene is further 
downregulated in metastases compared to both primary 
tumour and the normal counterpart (Supplementary 
Table S1). The median log2 expression value of ZFP36 
decreases from 8.7 of normal to 8.3 of CRC and to 8.2 
of liver metastasis. As shown in table Supplementary 
Table S2, ZFP36 results significantly differentially 
expressed in CRC vs Normal and Mts vs Normal 
comparisons from differential expression tests. However, 
it does not result significantly differentially expressed in 
Mts vs CRC comparison, even though the tendency toward 
decrease is constant when considering the progression 
represented by Normal, CRC and Mts samples. Figure 1B 
and 1C are respectively the results of an immunoblot and 
a real-time PCR; they both show that ZFP36 is expressed 
in the cell line SW480, which is derived from primary 
colon carcinoma, while it is strongly down-regulated in 
SW620, a cell line derived from a metastatic form of the 
same tumour. Altogether these results suggest that ZFP36 
seems to undergo a more pronounced down-regulation in 
metastases rather than in primary tumours compared to 
normal tissues.
ZFP36 ectopic expression determines a shift 
from mesenchymal to epithelial phenotype
 Figure 2 shows Western blot analysis of EMT 
markers E-cadherin, Zona Occludens 1 (ZO-1), N-cadherin 
and Vimentin in three CRC cell lines (SW480, SW620 
and HCT116) following ZFP36 ectopic expression. It 
appears that ZFP36’s increase of expression determines 
a down-regulation of mesenchymal markers N-cadherin 
and Vimentin and the up-regulation of epithelial markers 
E-cadherin and ZO-1 (densitometric analysis reported in 
Supplementary Figure S1). Figure 2, panels A, B and C 
also display an immunofluorescence showing E-cadherin 
expression following ZFP36 restoration in SW480, 
HCT116 and SW620 cell lines. Images show that, 
following ZFP36 over-expression, E-cadherin results to 
be increased and clearly localised on the cell membrane.
To test whether the activity of intercellular junctions 
was increased by ZFP36, we performed impedance-based 
experiments aimed to measure the barrier function of 
the cellular monolayer. Thus, we recorded the resistance 
opposed by the cellular monolayer to an electric field of 
4000 Hz, which represents the best condition in order to 
assess the strength of intercellular epithelial junctions in 
this kind of experiments. In this setting, electric current 
preferentially flows in the space between cells, which is 
usually closed by intercellular contacts in the case of an 
epithelial monolayer. Therefore, the stronger the cellular 
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junctions, the higher the resistance contrasting the flow. 
The results of these experiments performed on SW480, 
HCT116 and SW620 cells are shown in Figure 3, panels 
A, B and C. They suggest that ZFP36-overexpressing cells 
exhibit an augmented resistance of the cellular monolayer 
in comparison to control cells. Changes in the normalised 
resistance in function of time are reported in the graphics 
on the left-hand side of panels A–C, where 0 h corresponds 
to the time after seeding. In the graphics on the right-hand 
side of the same panels, the same parameter is recorded for 
5 hours after the samples had reached the complete cellular 
confluence, and then averaged and expressed as a fold 
change. Precisely, cellular resistance significantly increases 
of the 40% in SW480, of 20% in HCT116 and of 20% in 
SW620 cells.
ZFP36 ectopic expression inhibits colony 
formation, growth in suspension and migration 
capability of CRC cell lines 
Figure 4, panels A, C and E shows the results of 
several soft agar assays performed on SW480, HCT116 
and SW620 cell lines showing that ZFP36 over-expression 
determines a drastic decrease in colony formation. 
Figure 4, panels B, D and F shows the results of a 
Dispase assay suggesting that CRC cell lines ectopically 
expressing ZFP36 have a lower capability of growing in 
the absence of a substrate compared to controls, therefore 
displaying a higher susceptibility to anoikis. 
Another important feature of cells undergoing 
EMT is the acquisition of migratory abilities. For this 
reason, we speculated that ZFP36 overexpression could 
Figure 1: Analysis of ZFP36 expression in CRC-related samples. (Panel A) Boxplot of ZFP36 mRNA Log2 expression levels 
evaluated in a GEO database of gene expression profiles derived from 23 normal colon mucosa (Normal), 30 primary colon carcinoma 
(CRC) and 27 liver metastases (Mts) samples. The thick line indicates the median value, the coloured box indicates the interquartile range 
and the whiskers the minimum and maximum values excluded outliers. Open circles represent data points outside the whiskers. (Panel B) 
ZFP36 protein expression in CRC cell lines derived from primary tumour (SW480) and matched metastatic lesion (SW620). Vinculin 
was used as loading control. (Panel C) ZFP36 mRNA levels detected in SW480 and SW620 cell lines through qRT-PCR. Results are 
represented as means of two experiments (+/− SEM) and GAPDH was used as endogenous control. *p < 0.05.
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decrease cellular motility. Surprisingly, the results of an 
assay performed with the ECIS machinery (Figure 5A) 
– where the wound in cellular monolayer was achieved 
by a high voltage pulse, and the efficiency of gap closure 
was assessed by measuring the cellular impedance – 
demonstrated that, comparing control cells and ZFP36 
overexpressing cells, there is no significant difference 
in the time required for the gap to close. Even a wound 
healing assay, shown in Figure 5B, did not provide clear 
evidence that SW480 or HCT116 over-expressing cells 
are slower in repairing the wound compared to their 
controls. To further investigate this matter, we performed 
a transwell assay. Results (Figure 5C) show a difference 
in the migration capability of control cells and ZFP36 
Figure 2: Analysis of epithelial markers in ZFP36 overexpressing cells. SW480 (Panel A), HCT116 (Panel B) and SW620 
(Panel C) were infected with empty vector (pRRL) or ZFP36-overexpressing vector (ZFP36) and the corresponding total protein lysates 
were analysed through Western blot using antibodies against E-cadherin, ZO-1, N-cadherin, Vimentin and ZFP36. Actin was used as a 
loading control. The same cells were seeded on glass dishes and subsequently subjected to immunofluorescence analysis with antibody 
against E-cadherin (red) to assess its sub-cellular localization. Nuclei were counterstained with DAPI (blue).
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expressing cells. Indeed, the count of migrated nuclei 
shown in panel C, reveals that both SW480-ZFP36’s and 
HCT116-ZFP36’s migration efficiency is halved compared 
to control cells. The same assay on SW620 cells is not 
shown since these cells do not have migration ability 
on transwell. Altogether, these data suggest that ZFP36 
expression has higher impact on anoikis and anchorage 
independent growth rather than on migration. 
Figure 3: ZFP36 overexpression increases epithelial barrier function. SW480 (Panel A), HCT116 (Panel B) and SW620 
(Panel C) infected with empty vector (pRRL) or ZFP36-overexpressing vector (pRRL-ZFP36) were seeded on uncoated gold microelectrodes 
and subjected to a small alternating current. Immediately after seeding, resistance at 4000 Hz was recorded every 5 minutes for at least 
45 hours. Graphs on the left-hand side of the panel show the mean of the normalized resistance for three different experiments plotted 
in function of time (+/−SEM). The histograms on the right-hand side of each panel summarize the results described in the graphs: 
approximately 48 hours after seeding, resistance at 4000 z became stable and was recorded for further 5 hours. Values obtained during the 
last 5 hours were averaged and normalized on pRRL values. *p < 0.05, **p < 0.001.
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MACC1, ZEB1 and SOX9 are directly targeted 
by ZFP36
 Figure 6, panel A shows the expression of 
MACC1, ZEB1 and SOX9 in the CRC dataset previously 
described. The expression levels of such genes were 
analysed since they all carry an ARE sequence in the 
3ʹUTR region of their mRNAs (Figure  6, panel B) and 
therefore can be considered as putative ZFP36 targets. 
MACC1 and SOX9 show a progressive increase in 
tumour and metastases compared to normal tissue with 
a median log 2 expression value increase from 6.8 to 8.7 
in normal cells, and from 8.0 to 8.8 in primary tumour 
cells (Supplementary Table S2). On the contrary, ZEB1 
expression seems to decrease in tumour versus normal 
(median log2 expression value from 7.6 of normal to 6.9 
of tumour and 6.6 of metastasis). The latter observation 
is controversial since ZEB1 is widely recognized in 
literature as upregulated in CRC and to be responsible for 
EMT [15–18].
Figure 6, panel C is a real time PCR analysis 
showing that expression of ZEB1, MACC1 and SOX9 
mRNA decreases in HCT116 and SW480 cells following 
ZFP36 over-expression. Panel D shows Western blots 
confirming at the protein level that the expression of 
the putative targets decreases in HCT116 and SW480 
Figure 4: ZFP36 overexpression impairs anchorage-independent-growth and sensitizes to anoikis. SW480 (Panel A), 
HCT116 (Panel C) and SW620 (Panel E) infected with empty vector (pRRL) or ZFP36-overexpressing vector (pRRL-ZFP36) were seeded 
in soft-agar medium (DMEM + 0.3% Agar) and allowed to form colonies. The efficiency in colonies formation was then evaluated by 
randomly selecting 10 optical fields for each plate and calculating the average number of colonies. The histograms represent these figures 
as the mean of three independent experiments +/−SEM. Photographs show the crystal-violet staining of one representative experiment. 
In (panels B, D and F) equal amounts of respectively SW480, HCT116 and SW620 infected with pRRL or ZFP36 vectors were seeded 
in presence of Dispase to prevent cell adhesion (in suspension). Vital cells were then counted through Trypan blue exclusion assay. 
Results were normalized on the number of seeded cells and reported as the mean of three independent experiments (+/− SEM). *p < 0.05, 
**p < 0.001.
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cells following ZFP36 ectopic expression (densitometric 
analysis reported in Supplementary Figure S2).
To demonstrate that MACC1, ZEB1 and SOX9 are 
directly targeted by ZFP36, we performed a luciferase 
reporter assay, generating luciferase reporter constructs 
(pGL3-based) allowing transcription of a luciferase mRNA 
carrying the 3ʹ UTRs of MACC1, ZEB1 and SOX9. The 
results are described in Figure 6, panel E; they show that 
co-expression of the three vectors encoding the different 
3ʹUTRs with a vector expressing ZFP36 impairs protein 
production by either promoting mRNA degradation or by 
inhibiting mRNA translation, thus suggesting that ZFP36 
is capable of directly binding and therefore destabilizing 
the mRNAs of MACC1, ZEB1 and SOX9.
Figure 5: ZFP36 restoration in CRC cell lines exerts minor effects on cellular migration. (Panel A) SW480, HCT116 and 
SW620 infected with empty vector (pRRL) or ZFP36-overexpressing vector (pRRL-ZFP36) were seeded on uncoated gold microelectrodes 
and subjected to a small alternating current. After reaching complete confluence, a wound in the cellular layer was produced by applying 
a high voltage pulse and the recovery of the cellular monolayer was monitored by measuring Resistance at 4000 Hz. The graphs shown 
represent a single experiment. (Panel B) SW480, HCT116 and SW620 infected with empty vector (pRRL) or ZFP36-overexpressing vector 
(pRRL-ZFP36) were grown until complete confluence, and a scratch on cellular monolayer was performed with a pipette tip. The results of 
one representative experiment are shown in the photographs. (Panel C) SW480 and HCT116 infected with empty vector (pRRL) or ZFP36 
overexpressing vector (pRRL-ZFP36) were serum-starved and seeded inside the upper chamber of 8 μm-pore transwell insert. Cells were 
then allowed to migrate towards a chemo-attractant stimulus (FBS) for 16 hours. Migrated nuclei were stained with DAPI and quantified 
by taking random pictures. Results obtained were normalized on the pRRL values and represented as the mean of three independent 
experiments.
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ZFP36 expression in CRC cell lines is inversely 
correlated to Wnt/β−catenin pathway activation 
In the absence of genomic loss or described 
mutations, we investigated whether the down-regulation 
of ZFP36 observed in CRC might depend on the activity of 
specific pathways. Since Tcf/β-catenin abnormal signalling 
is a hallmark of CRC, we looked for a relation between 
this pathway and ZFP36 expression. To do so, we used the 
Tcf/β-catenin signalling inhibitor FH535. Figure 7, panel 
Figure 6: Validation of three novel ZFP36 target genes involved in EMT. (Panel A) Boxplot of Log 2 expression values 
of MACC1, SOX9 and ZEB1 in 23 normal colon mucosa (Normal), 30 primary colon carcinoma (CRC) and 27 liver metastases (Mts) 
samples. The thick line indicates the median value, the coloured box indicates the interquartile range and the whiskers the minimum and 
maximum values excluded outliers. Open circles represent data points outside the whiskers. (Panel B) Schematic representation of the 
3ʹUTRs sequences of MACC1, SOX9 and ZEB1. A-U rich sequences (ARE) are highlighted in bold. (Panel C) HCT116 and SW480 cells 
were transfected with an empty vector (pCDNA3.1) or a ZFP36-overexpressing vector (pCDNA3.1-ZFP36). RNA was extracted after 
48 hours and MACC1, SOX9, ZEB1 mRNA levels were analysed through qRT-PCR analysis. Results are represented as means of three 
experiments (+/−SEM) and GAPDH was used as endogenous control. *p < 0.05. (Panel D) HCT116 and SW480 were infected with an 
empty vector (pRRL) or a ZFP36-overexpressing vector (ZFP36) and corresponding total protein lysates were analysed through Western 
blotting techniques with antibodies against ZEB1, MACC1, SOX9 and ZFP36. Actin was used as loading control. (Panel E) A fragment 
of the 3ʹUTRs of MACC1, SOX9 and ZEB1 was cloned in a pGL3 vector, downstream of the Luciferase gene. These constructs where 
co-transfected with a ß-gal reporter plasmid and with an empty vector (pCDNA3.1) or ZFP36 overexpressing vector (pCDNA3.1-ZFP36) 
in HEK293T cells. Cells were harvested after 48 hours, luciferase activity was measured and normalized over ß-gal signals. Results are 
represented as means of three independent experiments +/−SEM. *p < 0.05, **p < 0.001, ***p < 0.0001.
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A displays a real time PCR showing that administration of 
FH535 determines an increase in ZFP36 expression. Panel 
B is a Western blot showing that FH535 administration 
increases ZFP36 expression also at the protein level.
In order to further clarify the relation between 
Tcf/β-catenin signalling and ZFP36 expression, HCT116 
cells were cultured with a medium enriched in Wnt3a 
concentration. Although this cell line expresses very low 
Figure 7: Wnt/β-catenin pathway inversely regulates ZFP36 expression. (Panel A) HCT116 were treated with FH353 20 μM 
or vehicle (DMSO) for the indicated time. RNA was extracted, retro-transcribed and used for real-time qRT-PCR analysis of ZFP36 and 
TCF7L2 transcripts. Results were normalized on DMSO values at each time point. Histograms represent the mean of two independent 
experiments (+/−SEM), GAPDH was used as endogenous control. *p < 0.05. (Panel B) HCT116 treated as in panel A were lysed and 
equal amounts of total protein extracts were loaded on a SDS-PAGE and subsequently analysed through Western blot techniques with an 
antibody against ZFP36. Actin was used as loading control. (Panel C) HCT116 and SW480 were treated with conditioned medium obtained 
from empty vector cells (E.V medium) or Wnt3a overexpressing cells (Wnt3a medium). After 24 hours, cells were collected, lysed and 
equal amounts of protein were loaded on SDS-PAGE and subsequently analysed through Western blot technique with an antibody against 
ZFP36. Actin was used as loading control. (Panel D) HCT116 were treated with E.V. medium and Wnt3a medium supplemented with 
Cyclohexymide (CHX) or DMSO (not indicated). After the indicated amount of time, RNA was extracted, retro-transcribed and used for 
real-time PCR analysis of ZFP36 and Axin2 transcripts. Results were normalized on E.V. medium values at each time point. Histograms 
represent the mean of four independent experiments (+/−SEM), GAPDH was used as endogenous control. *= p < 0.05 , **= p < 0.001. 
§=p <  0.05 if t-test was performed on the values obtained from Wnt3a-CHX treated cells in comparison to E.V medium-CHX treated cells. 
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levels of ZFP36, administration of Wnt3a determines a 
further decrease of its expression together with an increase 
of Axin2 expression, which is a well-known target of 
β-catenin signalling (Figure 7C).
These observations generate two main hypotheses: 
the first is that ZFP36 transcription could be downregulated 
by a repressor induced by Wnt3a treatment, while the 
second one is that β-catenin could directly repress ZFP36. 
In the attempt to clarify this issue, we took advantage of 
Cycloheximide (CHX), a molecule that inhibits protein 
synthesis. Evaluation of expression levels of Axin2, a 
well-known β-catenin target gene, was used as positive 
control of the effectiveness of Wnt3a usage. Treatment 
with Wnt3a conditioned medium alone for 3, 6 and 9 hours 
resulted in a time dependent increase of Axin2 transcripts 
and to a slight decrease in ZFP36 mRNA (Figure  7D). 
The addition of CHX in culture medium surprisingly 
resulted in a strong increase of ZFP36 mRNA (Figure 7D), 
a phenomenon previously described in two other papers 
and not linked to an increase in protein levels [19, 20]. 
Interestingly, also in presence of CHX, Wnt3a-treated cells 
displayed reduced levels of ZFP36 transcript compared to 
cells receiving E.V. medium, with a decrease of 30% after 
6 hours of treatment (Figure 7D). These data demonstrate 
that inhibition of protein synthesis does not affect Wnt3a-
mediated repression of ZFP36, thus suggesting that 
this could be a direct effect of β-catenin/TCF complex. 
Another clue in favour of this hypothesis is represented 
by the presence of some TCF7L2 putative binding 
sites in the promoter of ZFP36, and by the proof of the 
effective binding of TCF7L2 to some of these sequences, 
provided by Encode project data (https://genome.ucsc.edu/
ENCODE/).
DISCUSSION
ZFP36 was originally described as an active 
regulator of the inflammatory response. Today several 
publications show that its expression is commonly 
deficient in a large number of cancer cell types when 
compared to normal cells [21]. Moreover, its expression 
seems to counteract malignant progression by interfering 
with different pathways, depending on the disease model 
[22–24].
In this work we described three new ZFP36 targets, 
each one containing ARE sequences in their 3ʹ UTR: 
ZEB1, SOX9 and MACC1. These genes are well known 
for being deregulated in CRC and for being responsible 
of epithelial to mesenchymal transition in synergy with 
Twist1 and Snail1[5–9], genes which were very recently 
described as ZFP36 targets as well [14].
From a functional point of view, we confirmed that, 
by negatively regulating its targets’ expression, ZFP36 
restoration has an impact on EMT and, as described 
in the results section with reference to the ECIS and 
immunoflurescence assays, it seems to be capable of 
bringing back the cells to a more epithelial-like phenotype. 
Indeed, these cells lose the ability to grow in soft agar 
and display a higher susceptibility to anoikis while, in our 
study, we observed a minor effect on the ability of ZFP36 
to impinge on migration capacity.
Although it is quite recognized that ZFP36 
expression is lost in several malignancies, much less is 
known concerning the mechanisms determining this 
event. Neither specific mutations have been described, 
nor genomic loss has been singled out. Epigenetic 
causes have been suggested [25]. However, it can be also 
hypothesised that, since loss of ZFP36 strongly fosters 
tumour progression, this event can occur in different 
cell contexts through the modulation of the pathways 
that are crucial to a specific tumour. To this regard, we 
observed that ZFP36 expression in CRC cell lines is 
inversely correlated to Wnt/β-catenin pathway activity. 
It remains to fully understand whether this depends 
directly on β-catenin or indirectly on the activity of 
another repressor activated by the pathway. Based on 
the CHX experiment shown in Figure 7, we are inclined 
towards the first hypothesis. Interestingly, there are only 
a couple reports describing the ability of β-catenin to act 
as a transcriptional repressor rather than as an activator 
[26–28]. The inverse trend between Wnt/β-catenin and 
ZFP36 is surely noteworthy and deserves wider studies 
that would help clarifying the mechanisms underlying the 
loss of ZFP36 in specific cancers.
MATERIALS AND METHODS
Expression data 
We considered the expression profiles of ZFP36, 
MACC1, SOX9 and ZEB1 genes in colon cancer 
patients, using a dataset available at the GEO database 
(GSE35834). This dataset reports expression estimations, 
obtained with GeneChip Human Exon 1.0 ST (Affymetrix) 
platform, of 22517 genes in 80 samples, including 23 
normal colon mucosa (Normal), 30 primary colorectal 
tumours (CRC) and 27 liver metastases (Mts) obtained 
from 46 patients diagnosed with colorectal carcinoma at 
TNM stage IV, who underwent surgery at the University of 
Padova (Surgery Unit, Department of Surgery, Oncology 
and Gastroenterology) in the period 1994–2008 [29, 30].
Differential expression analysis was performed 
using limma package, available from BioConductor 
for the R statistics environment (BioConductor, www.
bioconductor.org), setting p-value < 0.05 and using 
Benjamini Hochberg (BH) method to adjust p-value.
Cell culture and treatment 
SW480 and SW620 cell lines were kindly gifted 
by Prof Alberto Bardelli, (University of Turin). HCT116 
and HEK293T cells were purchased from ATCC. All cell 
Oncotarget11www.impactjournals.com/oncotarget
lines were grown in DMEM supplemented with 10% FBS 
(Sigma), 2 mM L-glutamine and penicillin/streptomycin 
(10 U/ml) (Euroclone) at 37°C under a 5% CO2 
atmosphere. FH535 (Sigma) and Cyclohexymide (Sigma) 
were dissolved in DMSO and diluted in colture medium at 
a concentration of 20 μM. and 25 μM respectively. In both 
cases, control cells received the same amount of DMSO.
Plasmids
ZFP36 coding sequences was previously cloned 
into pCDNA3.1 vector and pRRL lentiviral vector. The 
ARE-containing regions of the 3ʹUTRs of MACC1, 
SOX9 and ZEB1 were amplified by RT-PCR on total 
RNA extracted from HCT116 cells using specific primers: 
(MACC1 DP: AGTTCCTCAGGCTTTTTGTCT with 
MACC1 RP: AGAACTTCACTCTCACTAAACC; 
SOX9 DP: CCTGTGCCTCTCAGAACACC with 
SOX9 RP: GCTGGGAGGGAAACAAGTGA; ZEB1 
DP: TGGCTCATAACTGTTTCCAAATGT with ZEB1 
RP: AAGGCAATAGAAAAAGAAGGCATAA). The 
amplified fragments were then inserted into the pCR2.1-
TOPO T/A cloning vector and fully sequenced. These 
fragments were then excised with KpnI and XhoI and 
cloned into pGL3-Promoter Vector (Promega) that had 
previously been modified in order to transfer the multiple 
cloning region downstream the luciferase reporter gene. 
Human Wnt3a coding sequence was amplified by RT-PCR 
on total RNA extracted from HCT116 cells using specific 
primers (DP: CGATGGCCCCACTCGGATAC and RP: 
GCGGCCGGTGCCTACT). The amplified fragments 
were then inserted into the pCR2.1-TOPO T/A cloning 
vector and fully sequenced. Wnt3a coding sequences 
was then excised with XhoI and KpnI and cloned into 
pCDNA3.1 vector digested with the same enzymes.
Western blot analysis
Total protein extracts were obtained by resuspending 
and vortexing cell pellets in small volumes of RIPA buffer 
containing 50 mM TRIS-HCl (pH 7.4), 150 mM NaCl, 
1% NP-40, 1 mM sodium deoxycholate, 1 mM sodium 
orthovanadate and with added 1 mM EDTA and Complete 
Protease Inhibitor Cocktail (Roche Applied Science) 
and quantified. Equal amounts of proteins were loaded 
onto a SDS-Polyacrilamide gels and transferred to a 
nitrocellulose sheet. The membranes were then blocked 
with 5% non-fat milk in TBST 0.1% and immunoblotted 
overnight at 4°C with different primary antibodies listed 
below together with their working dilution: N-cadherin 
(910920 BD Transduction Laboratories); Vimentin (Dako 
MO725); E-Cadherin (610181 BD); ZO-1 (Zymed 61-
7300); MACC1 (Bioss bs-4293R); SOX9 (Bioss bs-
4177R); ZEB1 (Sigma HPA027524); ZFP36 (S. Cruz 
Biotechnology sc-14030 ). Blots were then incubated 
either with anti-Rabbit or anti-Mouse (Santa Cruz 
Biotechnology, sc-2054 and sc-2005 respectively) IgG-
HRP antibodies and detected using BM Chemiluinescence 
Blotting Substrate (Roche Applied Science).
RNA extraction and qRT-PCR 
Total RNA was extracted with PureLink RNA 
mini Kit (Invitrogen), quantified with Nanodrop 2000 
and retro-transcribed with High Capacity cDNA KIT. 
The obtained cDNA was qPCR quantified using TaqMan 
Gene Expression Master Mix (Applied Biosystems) with 
specific primer pairs using the ABI PRISM 7900 HT 
Detection System (Applied Biosystems). TaqMan Gene 
Expression assays for GAPDH, ZFP36, TCF7L2 and 
Axin2 transcripts were purchased from Invitrogen.
Anchorage-independent growth assays
Anchorage-independent growth assays were 
performed in triplicate in 35 mm well plates. 
72 hours after infection, cells were trypsinised in order 
to achieve a single-cell suspension and diluted at the 
same concentrations. Equal amounts of cells were then 
resuspended in complete DMEM supplemented with 0.3% 
of Bacto Agar (Sigma) and seeded on the top of a thick 
layer of DMEM supplemented with 0.6% Bacto Agar. For 
SW620 and HCT116, 5000 cells were seeded and 10000 
for SW480. After 2–3 weeks, colonies were quantified by 
taking photographs of 10 random fields. For crystal violet 
staining dishes were fixed with methanol, stained for 
3 hours with 0.01% crystal violet in PBS 40% methanol 
and de-stained with PBS overnight.
Lentivirus production and infection 
Lentiviral particles production was performed as 
previously described [31]. Briefly, pRRL vectors were 
co-transfected with packaging plasmids in HEK293T 
and the resulting supernatant was concentrated through 
ultracentrifugation at 19000 rpm for 2.5 hours. Target cell 
lines was infected at MOI 3 overnight with Polybrene. 
Unless otherwise stated, infected cells were subject 
to different experimental procedures after 72 hours 
from infection and with a maximum of one week from 
infection.
Anoikis assay 
Infected cells were seeded in a 24-wells plate 
at a density of 200000 cells/well in 0.5 ml of DMEM 
supplemented with 2 U/ml of Dispase (BD Biosciences) 
which prevents cell adhesion. Subsequently cells were 
grown for 72 hours and cellular viability was assessed 
every day through Trypan blue exclusion assay. Number 
of cells expansion were normalized on the number of cells 
seeded at 0 hours.
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Wound healing (scratch) assay 
Infected cells were grown in 12-wells plates until 
complete confluence and then scratched with a p200 
pipette tips. Photographs were taken at 0 hours and every 
day, until gap closure. 
Luciferase assay
For luciferase assays, HEK293T cells were plated at 
a density of 50000 cells/well the day before transfection 
in 24-wells plates. In a typical assay, each well received 
200 ng of pGL3-based reporter constructs (described 
in Plasmids chapter), 200 ng of CMV- b-galactosidase 
plasmid (Clontech Laboratories) and 10 ng of pcDNA3.1 
o pCDNA3.1-ZFP36. Transfections were performed using 
Lipfectamine 2000 (Invitrogen). After 48 hours, cells were 
harvested and cell lysates were assayed for luciferase and 
b-galactosidase activity. Luciferase values was normalized 
on protein concentration and b-galactosidase activity. Each 
transfection was done in duplicate, and the plotted results 
represent the average of four different experiments, error 
bars represent SEM (*p < 0.05; **p < 0.01).
Immunofluorescence 
Briefly, infected cells were grown for 48–72 hours on 
uncoated coverslips then fixed with 4% paraformaldehyde 
for 10 minutes and incubated with blocking solution 
containing 0.1% Saponin (Sigma) and 2% BSA (Sigma) 
in PBS for 30 minutes. Primary antibody was diluted 1:50 
in blocking solution and incubated overnight in humidified 
chamber at 4°C. Subsequently slides were incubated with 
fluorescently labelled secondary antibody Alexa Fluor 
(Invitrogen) and nuclei were counterstained by DAPI 
(Sigma-Aldrich). Finally, slides were analysed using a 
Carl Zeiss Axioskop 40 fluorescent microscope.
Wnt3a conditioned medium production
pCDNA-WNT3a vector (described in Plasmids 
section) was linearized with SspI and transfected into 
HCT116 cells. In order to obtain stably transfected cell 
lines HCT116 was selected with 0.9 μg/ml G418. After 
2 weeks of selection, cells were split at 1:8 ratio in absence 
of G418 and supernatant was collected twice, after 72 h 
and after further 48 h. The same procedure was performed 
with pCDNA3.1 empty vector. The so obtained medias 
were filtered 0,45 μm and kept at –80°C.
Epithelial barrier functions experiments
The assessment of epithelial barrier functions 
was performed with Electric Cell-substrate Impedance 
Sensing (ECIS) Zq instrument (Applied Biophysics). 
This instrument applies a small alternating current while 
recording the impedance, and thus the resistance, of the 
cellular layer. In this case, infected cells were seeded at 
105cells/cm2 onto uncoated gold microelectrodes in ECIS 
cultureware (8W10E+) and impedance was recorded 
immediately after seeding and for at least 48 hours. 
The results display the resistance recoded at 4000 Hz 
and normalized on the values recorded at 0 hours and 
represents the mean of three independent experiments +/−
SEM.
Transwell assays
 Infected cells were serum starved for 6 hours 
and then resuspended in DMEM 0.5% FBS, 0.1% BSA. 
60000 SW480 were then seeded in the upper chamber 
of transwell inserts (8 μm pore and 6.5 mm diameter 
from Corning) and DMEM 10% FBS was added in the 
lower chamber in order to provide a chemoattractant 
stimulus. After 16 hours migrated cells were removed 
with a cotton swab and the inserts were fixed with cold 
methanol for 5 minutes and stained with DAPI for 10 
minutes. Permeable membranes were then excised with 
a blade and mounted on a glass slide with mounting 
medium. Quantification of migrated cells were performed 
by counting the migrated nuclei on 10 random fields and 
normalized over pRRL values. Results are the mean of two 
independent experiments +/−SEM. 
Impedance based scratch assays 
Infected cells were seeded on ECIS cultureware 
(8W1E array) and allowed to reach confluence. Then 
a wound in the cellular monolayer was generated in by 
applying a 3 mA, voltage pulse for 20 s, and recovery 
of the layer was monitored by measuring Resistance at 
4000 Hz.
Statistical analysis 
All experiments were repeated at least three times, 
unless otherwise stated, and the results presented in terms 
of mean ± S.E.M. values. Pairwise comparisons were 
carried out using the Student’s t-test procedure. Results of 
statistical analysis were considered significant at p values 
< 0.05 (*= < 0.05, **= < 0.001, ***= < 0.0001).
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